

Making Cancer History*


Lung Cancer Screening

This practice algorithm has been specifically developed for MD Anderson using a multidisciplinary approach and taking into consideration circumstances particular to MD Anderson, including the following: MD Anderson's specific patient population; MD Anderson's services and structure; and MD Anderson's clinical information. Moreover, this algorithm is not intended to replace the independent medical or professional judgment of physicians or other health care providers. This algorithm should not be used to treat pregnant women.

Note: Screening is only intended for asymptomatic individuals. Individuals undergoing lung cancer screening should have a 10-year life expectancy and no co-morbidities that would limit the diagnostic evaluation or treatment of any identified problem. The screening technique should be performed with a consistent technique and process.

PRESENTATION





¹Lung Cancer symptoms include:

- Cough
- Hoarseness
- Unexplained weight loss
- Hemoptysis

²Examples of Moderate risk include but are not limited to:

• Previous history of other malignancies which would provide a higher risk for secondary lung cancer (e.g. patients with head and neck cancer related to smoking)

• Less than 30 pack years of smoking history or age less than 55 years

³Quit within past year

⁴Quit within previous 15 years.

SCREENING



Lung Cancer Screening

Making Cancer History®

This practice algorithm has been specifically developed for MD Anderson using a multidisciplinary approach and taking into consideration circumstances particular to MD Anderson, including the following: MD Anderson's specific patient population; MD Anderson's services and structure; and MD Anderson's clinical information. Moreover, this algorithm is not intended to replace the independent medical or professional judgment of physicians or other health care providers. This algorithm should not be used to treat pregnant women.

Note: Screening is only intended for asymptomatic individuals. Individuals undergoing lung cancer screening should have a 10-year life expectancy and no co-morbidities that would limit the diagnostic evaluation or treatment of any identified problem. The screening technique should be performed with a consistent technique and process.

SUGGESTED READINGS

The National Lung Screening Trial Research Team. (2011) Reduced lung-cancer mortality with low-dose computed tomographic screening. New Engl J Med. 365(1):395-409.

Flehinger B, Kimmel M, Melamed, M. (1992). The effect of surgical treatment on survival from early lung cancer. Implications for screening. Chest, 101:1013-1018.

Henschke C, McCauley D, Yankelevitz D, et al. (1999). Early Lung Cancer Action Project; overall design and findings from baseline screening. Lancet, 354, 99-105.

Page 2 of 3



Lung Cancer Screening

Making Cancer History®

THE UNIVERSITY OF TEXAS

MDAnderson

Cancer Center

This practice algorithm has been specifically developed for MD Anderson using a multidisciplinary approach and taking into consideration circumstances particular to MD Anderson, including the following: MD Anderson's specific patient population; MD Anderson's services and structure; and MD Anderson's clinical information. Moreover, this algorithm is not intended to replace the independent medical or professional judgment of physicians or other health care providers. This algorithm should not be used to treat pregnant women.

Note: Screening is only intended for asymptomatic individuals. Individuals undergoing lung cancer screening should have a 10-year life expectancy and no co-morbidities that would limit the diagnostic evaluation or treatment of any identified problem. The screening technique should be performed with a consistent technique and process.

DEVELOPMENT CREDITS

This practice consensus algorithm is based on majority expert opinion of the Lung Cancer Screening workgroup at the University of Texas MD Anderson Cancer Center. It was developed using a multidisciplinary approach that included input from the following clinical staff.

Therese Bevers MD^T Powel Brown, MD Elise Cook, MD Robin Coyne, FNP, RN Joyce Dains, DrPH, JD, DNur, FNP-BCNAP Suzanne Day, FNP, RN George Eapen, MD^T Jeremy Erasmus, MD Myrna Godoy, MD Ernest Hawk, MD Marita Lazzaro,, RN MS ANP Ana Nelson, FNP, RN Lonzetta Newman, MD Tilu Ninan, RN, MSN, ANP[†] Sally Scroggs, LD, RD Stephen Swisher, MD^{T}

^T Core Development Team